EMEA-001656-PIP02-19
Key facts
| Active substance |
Momelotinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0249/2019
|
| PIP number |
EMEA-001656-PIP02-19
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of myelofibrosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +1 438-899-8201 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|